WebResults: ION-827359 was well-tolerated with an acceptable safety profile after multiple inhalations. The rate of adverse events was similar between ION-827359 and placebo … WebBackground: Eluforsen is an antisense oligonucleotide designed to bind to the mRNA region around the F508-encoding deletion and restore the cystic fibrosis transmembrane …
Intratracheally administered LNA gapmer antisense …
WebA study medication called ION-827359 is being developed to treat lung disease symptoms in people with cystic fibrosis. The study medication is intended to help treat the thick mucus … Web12 aug. 2024 · The BALANCE-CFTM 1 phase II trial in patients with CF was safe, but did not demonstrate a potential for clinical benefit, and development has been terminated. … monash scholarship international student
Ionis ION-827359-CS1 European Cystic Fibrosis Society (ECFS)
Web18 jun. 2024 · The purpose of this study was to evaluate the effect of ION-827359 on forced expiratory volume in 1 second (FEV1) in participants with mild to moderate COPD with … WebStrong evidence of tolerability and safety at the doses and regimens tested is demonstrated and supports further investigation of ENaC ASO ION-827359 in patients with cystic … Web1 jan. 2024 · Inhalation of small molecule drugs has proven very efficacious for the treatment of respiratory diseases due to enhanced efficacy and a favourable the… ibge areal